Bioventus expands team in Taiwan — 5 highlights

Written by Allison Sobczak | January 04, 2016 | Print  |

Bioventus is entering the patient care market in Taiwan with the launch of DUROLANE.

Here are five highlights:

 

1. DUROLANE is a single-injection joint-fluid osteoarthritis treatment based on a natural, safe and proven technology process called NASHA, which yields stabilizing hyaluronic acid.

 

2. Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint.

 

3. In Taiwan, DUROLANE is indicated for the treatment of mild to moderate osteoarthritis of the knee.

 

4. In Taiwan, Bioventus will be working with Eulogiums, a sales and marketing leader with more than 20 years of experience in orthopedics.

 

5. Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely.

 

More articles on devices and implants:
Zacks bumps RTI Surgical down to "sell" rating: 4 things to know
Eagle Asset Management buys 1.2M+ of NuVasive stock: 4 points
Cardinal Spine files form D for $1.25M in financing: 4 things to know

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months